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Cachexia is a wasting syndrome associated with cancer, AIDS, multiple sclerosis, and several other disease 
states. It is characterized by weight loss, fatigue, loss of appetite, and skeletal muscle atrophy and is associ-
ated with poor patient prognosis, making it an important treatment target. Ghrelin is a peptide hormone that 
stimulates growth hormone (GH) release and positive energy balance through binding to the receptor GHSR-1a. 
Only acylated ghrelin (AG), but not the unacylated form (UnAG), can bind GHSR-1a; however, UnAG and AG 
share several GHSR-1a–independent biological activities. Here we investigated whether UnAG and AG could 
protect against skeletal muscle atrophy in a GHSR-1a–independent manner. We found that both AG and UnAG 
inhibited dexamethasone-induced skeletal muscle atrophy and atrogene expression through PI3Kβ-, mTORC2-, 
and p38-mediated pathways in myotubes. Upregulation of circulating UnAG in mice impaired skeletal muscle 
atrophy induced by either fasting or denervation without stimulating muscle hypertrophy and GHSR-1a–medi-
ated activation of the GH/IGF-1 axis. In Ghsr-deficient mice, both AG and UnAG induced phosphorylation of 
Akt in skeletal muscle and impaired fasting-induced atrophy. These results demonstrate that AG and UnAG act 
on a common, unidentified receptor to block skeletal muscle atrophy in a GH-independent manner.
Introduction
Skeletal muscle atrophy involves massive loss of muscle structural 
proteins, which leads to muscle weight decrease and progressive 
loss of muscle function. Skeletal muscle atrophy is induced by 
muscle denervation and disuse, and it is also the key component 
of cachexia, a catabolic, debilitating response to several diseases. 
Cachectic patients not only sustain a decreased quality of life, but 
also face a worse prognosis of the underlying pathology, making 
cachexia an important target for treatment (1). Ghrelin is a circu-
lating peptide hormone, octanoylated on Ser3, that is mainly pro-
duced by the stomach, which, by acting on the hypothalamus and 
the pituitary, induces GH secretion and stimulates food intake and 
adiposity through binding to its receptor, GHSR-1a (2–5). In addi-
tion to its endocrine activities, ghrelin protects cardiac function 
after heart damage (6, 7). In vitro, ghrelin inhibits the apoptosis 
of cardiomyocytes and other cell types by activating PI3K/Akt and 
ERK-1/2 pathways (8–10). Acylated ghrelin (AG) and unacylated 
ghrelin (UnAG) are generated from the same precursor, which can 
be acylated by the specific intracellular ghrelin-O-acyltransferase 
GOAT (11, 12). UnAG, which is far more abundant in plasma than 
AG, does not bind to GHSR-1a, lacks any GH-releasing activity 
(13), and has been considered for many years to be the inactive 
product of ghrelin catabolism. However, UnAG shares with AG 
common high-affinity binding sites on several cell types lacking 
GHSR-1a, including myocardial and skeletal myocytes, where they 
stimulate survival and differentiation, respectively (8, 9, 14–16). 
Furthermore, UnAG regulates gene expression in fat, muscle, and 
liver independently of GHSR-1a (17).
In both human patients and experimental models, AG ameliorates 
cachexia induced by several pathological conditions (6, 7, 13, 18–21). 
Although AG may inhibit cachexia by stimulating food intake, posi-
tive energy balance, and release of GH and IGF-1, the mechanisms 
underlying its anticachectic activity have not been fully elucidated.
Since we have previously shown that AG and UnAG, indepen-
dently of GHSR-1a, inhibit apoptosis of cardiomyocytes by acti-
vating PI3K/Akt (8), a major antiatrophic signaling pathway (22, 
23), and stimulate C2C12 skeletal myoblast differentiation (16), 
we investigated whether AG and UnAG could protect skeletal mus-
cle from atrophy. Here, we provided evidence in vitro and in vivo 
that AG and UnAG, independently of GHSR-1a and activation of 
the GH/IGF-1 axis, trigger an antiatrophic signaling pathway by 
acting directly on the skeletal muscle, thereby protecting it from 
experimentally induced atrophy.
Results
AG and UnAG prevent dexamethasone-induced atrophy in C2C12-derived 
myotubes via mTORC2. C2C12 myotubes are a widely used model to 
study in vitro skeletal muscle atrophy induced by the synthetic glu-
cocorticoid dexamethasone (24–26). Muscle atrophy was measured 
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both as reduction of myotube diameter and as expression of the 
muscle-specific ubiquitin ligases Atrogin-1 (also known as MAFbx) 
and MuRF1, which drive muscle protein degradation in several 
models of muscle atrophy (24–27). Myotubes were treated with 
1 μM dexamethasone for 24 hours in the presence or absence of 
10 nM AG or UnAG, or with 10 ng/ml IGF-1 as a positive control of 
atrophy protection. Treatment with dexamethasone reduced myo-
tube diameters by 20% and induced Atrogin-1 and MuRF1 expres-
sion. AG and UnAG impaired both these effects (Figure 1, A–C).
Skeletal muscle atrophy and atrogene expression can be opposed 
by the activation of mammalian target of rapamycin (mTOR), which, 
by forming 2 distinct protein complexes, mTORC1 and mTORC2, 
triggers distinct pathways that lead, respectively, to increased pro-
tein synthesis and to inhibited protein degradation (28, 29). To assess 
whether mTOR mediates the signaling triggered by AG/UnAG, myo-
tubes were incubated with rapamycin, an inhibitor of mTORC1, 
which, upon prolonged treatment, also impairs the assembly of 
mTORC2 in several cell types, including C2C12 cells (refs. 30–32 
and Supplemental Figure 1, A and B; supplemental material avail-
able online with this article; doi:10.1172/JCI39920DS1).
Upon 24-hour treatment of atrophying myotubes with 20 ng/
ml rapamycin, the antiatrophic activity of AG/UnAG on myotube 
diameter was fully reverted (Figure 1D), which indicates that acti-
vation of mTOR is indeed required for the antiatrophic activity of 
AG and UnAG. Moreover, in the same assay, the antiatrophic activ-
ity of AG/UnAG was inhibited by 100 nM wortmannin, an inhibi-
tor of PI3K, whose product PI(3,4,5)P3 is essential for the activity 
of Akt, a substrate of mTORC2 that also mediates the activation 
of mTORC1 (29). These findings indicate that AG/UnAG antiat-
rophic activity requires both mTOR and Akt. Thus, we assayed the 
activity of both mTOR complexes. We evaluated mTORC2 activ-
ity as phosphorylation of AktS473, which, in turn, phosphorylates 
FoxO3aT32, thus preventing Atrogin-1 transcription (24, 25). AG/
UnAG, as well as IGF-1, induced phosphorylation of AktS473 and 
FoxO3aT32 (Figure 1, E and F), which indicates that they activate 
mTORC2-mediated pathways.
The activity of mTORC1 was assayed as phosphorylation of 
S6KT389, a direct substrate of mTORC1, and of its substrate 
S6S235/236, a ribosomal protein whose phosphorylation mediates 
protein synthesis (29). AG and UnAG did not induce phosphory-
lation of S6KT389 and S6S235/236 (Figure 1, G and H), nor protein 
synthesis (as measured by [3H]-leucine incorporation; Figure 1I) 
or myotube hypertrophy (Figure 1A). Conversely, IGF-1 induced 
S6KT389 and S6S235/236 phosphorylation, [3H]-leucine incorpora-
tion, and myotube diameter increase, as expected.
By silencing raptor and rictor, specific components of mTORC1 
and mTORC2, respectively (Figure 1J), we observed that down-
regulation of rictor abrogated the protective effect of both pep-
tides on dexamethasone-induced muscle atrophy, measured as 
myotube diameter, while it did not affect the antiatrophic activ-
ity of IGF-1 (Figure 1K). Conversely, raptor silencing impaired 
IGF-1 antiatrophic activity without affecting that of AG/UnAG. 
These results indicate that mTORC2 pathway mediates AG/
UnAG antiatrophic activity in C2C12 myotubes, without involv-
ing mTORC1-mediated protein synthesis.
To identify the signaling pathways differently activated by AG/
UnAG and IGF-1, we investigated the role of p38 serine kinase, 
whose activation by AG/UnAG mediates C2C12 myoblast differ-
entiation (16). In C2C12 myotubes, AG/UnAG, as well as IGF-1, 
induced phosphorylation of p38T180/Y182 (Figure 2A), and its phar-
macological inhibition impaired the antiatrophic activity of AG/
UnAG, but not of IGF-1 (Figure 2B).
Activation of p38 has been reported to downregulate Atrogin-1, 
thereby contributing to the protection of skeletal muscle from 
atrophy (33). On the other hand, p38 mediates induction of Atro-
gin-1 by TNF-α and oxidative stress and of MuRF1 by serum star-
vation (34–37). Inhibition of p38 with SB203580 reduced dexa-
methasone-induced expression of both Atrogin-1 and MuRF1; 
nevertheless, induction of Atrogin-1, but not MuRF1, was still 
significant (Figure 2, C and D). In the presence of SB203580, AG 
and UnAG, but not IGF-1, failed to further reduce the residual 
induction of Atrogin-1, which indicates that p38 mediates AG/
UnAG signaling in regulating Atrogin-1 expression.
To further characterize AG/UnAG antiatrophic activity, we 
treated C2C12 myotubes with NF449, a compound uncoupling 
Gαs from GPCRs, which inhibits antiapoptotic activity of AG and 
UnAG in pancreatic β cells (9, 38). NF449 completely abrogated 
AktS473 phosphorylation and antiatrophic activity of AG/UnAG 
without affecting IGF-1 activities (Figure 2, E and F), which sup-
ports the hypothesis that AG and UnAG act through a GPCR, as 
previously suggested (9).
PI3K α and β isoforms mediate Akt activation upon stimulation 
of tyrosine kinase receptors and GPCRs, respectively (39, 40). We 
dissected the contribution of PI3Kα and PI3Kβ to IGF-1 and AG/
UnAG antiatrophic activity using isoform-specific PI3K inhibitors. 
Whereas inhibition of PI3Kα by PIK-75 abolished IGF-1 antiat-
rophic activity, it did not affect AG/UnAG protection. Conversely, 
inhibition of PI3Kβ by TGX-221 impaired AG/UnAG antiatrophic 
activity while not affecting IGF-1 protection (Figure 2G). The 
involvement of PI3Kβ in AG/UnAG antiatrophic activity was fur-
ther supported by the finding that TGX-221 prevented AG/UnAG 
from reducing dexamethasone-induced Atrogin-1 expression (Fig-
ure 2H). Together, these data strongly suggest that AG/UnAG acts 
through GPCR-dependent signaling pathways involving a PI3K 
isoform distinct from that of IGF-1.
Glucocorticoids induce muscle mass reduction by also upregu-
lating the expression of myostatin, a TGF-β family member that 
acts as a negative regulator of muscle mass. Myostatin reduces the 
Figure 1
AG and UnAG protect C2C12 myotubes from dexamethasone-induced 
atrophy without induction of protein synthesis or hypertrophy. (A) Myo-
tube diameters were measured after 24-hour treatment in differentia-
tion medium (DM) with 10 nM AG, 10 nM UnAG, and/or 1 μM dexa-
methasone (DEXA). In every experiment, 10 ng/ml IGF-1 was used as 
positive control for antiatrophic/hypertrophic activity. (B and C) Atro-
gin-1 and MuRF1 expression analysis upon dexamethasone treatment 
with or without AG and UnAG. (D) Treatment with 100 nM wortman-
nin (W) or 20 ng/ml rapamycin (R) reverted the antiatrophic activity of 
AG and UnAG on myotube diameter. Control myotubes in differentia-
tion medium were treated with DMSO, a vehicle for both wortmannin 
and rapamycin. (E and F) Phosphorylation of AktS473 and FoxO3aT32, 
detected by Western blotting, upon treatment for 20 minutes with 1 μM 
AG or UnAG. Shown are representative blots and quantification of 3 
independent experiments. (G–I) IGF-1, but not AG and UnAG, induced 
protein synthesis, as determined by phosphorylation of S6KT389 (G) or 
S6S235/236 (H) and by incorporation of [3H]-leucine (I). (J) Effect of raptor 
and rictor silencing on protein levels, detected by Western blotting. (K) 
Silencing of rictor, but not of raptor, reverted the antiatrophic activity of 
AG and UnAG on the diameter of myotubes treated as in A. #P < 0.05, 
§P < 0.01 vs. DM control; *P < 0.01 vs. DEXA treatment.
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size of human skeletal muscle cell–derived myotubes by reducing 
mTOR/Akt/p70S6K signaling, while simultaneous treatment with 
IGF-1 restores myotube size, Akt phosphorylation, and protein 
synthesis (41, 42). In C2C12 myotubes, dexamethasone treatment 
actually induced the expression of myostatin, which was signifi-
cantly reduced by IGF-1. However, AG/UnAG had no effect on 
myostatin expression (Supplemental Figure 1C), providing further 
evidence that ghrelin and IGF-1 inhibit muscle atrophy through 
distinct, partially overlapping, mechanisms.
Tg mice with high levels of circulating UnAG are protected from fasting- 
and denervation-induced atrophy. To verify in vivo the relevance of the 
findings described above, we used a strain of Tg mice with cardiac-
specific ghrelin gene (Ghrl) expression. In these mice (referred to 
herein as Myh6/Ghrl), Ghrl overexpression in the heart results in 
Figure 2
AG and UnAG antiatrophic signaling 
is mediated by p38 and acts through a 
GPCR-dependent signaling pathway 
involving PI3Kβ. (A) Phosphorylation of 
p38T180/Y182, detected by Western blot-
ting, after 20-minute treatment with 1 μM 
AG or UnAG. Shown are representative 
blots and quantification of 3 independent 
experiments. (B) Treatment with the p38 
inhibitor SB203580 (5 μM) reverted the 
antiatrophic activity of AG and UnAG on 
myotube diameter upon treatment with 
dexamethasone. (C and D) Atrogin-1 and 
MuRF1 expression analysis upon dexa-
methasone treatment with or without AG 
and UnAG in the presence or absence 
of 5 μM SB203580. (E) AG and UnAG 
phosphorylation of AktS473 was abolished 
upon treatment with 10 μM NF449, a Gαs 
subunit–selective G protein antagonist. 
Shown are representative blots and quan-
tification of 3 independent experiments. 
(F) Treatment with 10 μM NF449 reverted 
the antiatrophic activity of AG and UnAG 
on myotube diameter upon dexametha-
sone treatment. (G) Treatment with 25 
nM PIK-75, an inhibitor of PI3Kα, abol-
ished the antiatrophic effect of IGF-1 on 
myotube diameter upon dexamethasone 
treatment, without affecting AG and UnAG 
activity. The antiatrophic effect was abro-
gated by treatment with 200 nM TGX-221, 
an inhibitor of PI3Kβ. (H) Atrogin-1 expres-
sion analysis upon dexamethasone treat-
ment with AG, UnAG, and IGF-1 in the 
presence or absence of 200 nM TGX-221. 
In experiments with SB203580, NF449, 
PIK-75, and TGX-221, control myotubes 
in differentiation medium were treated with 
DMSO, a vehicle for all these compounds. 
#P < 0.05, §P < 0.01 vs. DM control; 
*P < 0.05, **P < 0.01 vs. DEXA treatment.
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a 50-fold increase of circulating UnAG, without affecting AG lev-
els (Table 1), as previously observed in other Ghrl-overexpressing 
Tg mice (43–45). Ghrl mRNA overexpression was restricted to the 
myocardium of Myh6/Ghrl mice, without leakage in the skeletal 
muscle (Supplemental Figure 2A). Moreover, consistent with the 
inability of UnAG to activate GHSR-1a and to promote GH release 
and adiposity, Myh6/Ghrl mice did not feature any change in cir-
culating IGF-1 concentration, tibial and nasoanal length, BMI, 
or food intake compared with their WT littermates. In addition, 
fasting decreased IGF-1 and increased ghrelin circulating concen-
trations to the same extent in WT and Myh6/Ghrl mice (Table 1). 
These data strongly indicate that the upregulation of circulating 
UnAG in Myh6/Ghrl mice does not activate GHSR-1a in the pitu-
itary and hypothalamus, stimulate the GH/IGF-1 axis, or affect 
endogenous ghrelin regulation. Moreover, tissue expression of 
IGF-1, which in skeletal muscle may act locally in a paracrine/
autocrine manner (46), was not altered in Myh6/Ghrl mice, either 
in fed or in fasted animals (Supplemental Figure 2B).
Although AG and UnAG differently regulate insulin release and 
sensitivity (47), basal insulin level, glucose uptake, and insulin sen-
sitivity were not affected in Myh6/Ghrl mice (Table 1 and Supple-
mental Figure 2, C and D).
Notably, compared with WT animals, fed Myh6/Ghrl mice did not 
feature any difference in heart and gastrocnemius muscle weight 
(Table 1), fiber cross-sectional area (CSA) distribution, or hindlimb 
force (as measured by grasping test; Supplemental Figure 2, E and F), 
which indicates that high levels of circulating UnAG do not induce 
skeletal muscle hypertrophy in vivo, consistent with the inability of 
UnAG to induce hypertrophy in C2C12-derived myotubes.
To investigate whether UnAG might protect 
from muscle wasting, we induced skeletal muscle 
atrophy by food deprivation. After 48 hours of 
fasting, gastrocnemius weight was decreased by 
approximately 14% in WT mice, and by approxi-
mately 9% in Myh6/Ghrl mice, compared with 
fed animals (Figure 3A), which indicates that 
increased circulating UnAG results in 30% protec-
tion from fasting-induced loss in gastrocnemius 
mass. Accordingly, gastrocnemii CSA was reduced 
by 29% in WT mice and by 19% in Myh6/Ghrl mice 
compared with fed animals (Figure 3B), indicative 
of 34% protection. Similarly, extensor digitorum 
longus (EDL) muscle weight and mean fiber area 
of Myh6/Ghrl mice was reduced to a lesser extent 
than in WT animals (Figure 3, D and E). This pro-
tection was reflected by shift in CSA distributions 
of gastrocnemii and EDL — toward fibers with 
wider area — in Myh6/Ghrl compared with WT 
mice under fasting conditions (Figure 3, C and F).
After 48 hours of fasting, Atrogin-1 and MuRF1 
expression in gastrocnemii of WT animals dra-
matically increased. In Myh6/Ghrl mice, the 
induction of Atrogin-1 was significantly reduced 
by one-third, while MuRF1 was only slightly, not 
significantly, decreased (Figure 3, G and H).
Plasma levels of glycerol and FFAs did not 
change in fasted Myh6/Ghrl and WT mice (Sup-
plemental Figure 2, G and H), which indicates 
that fasting did not significantly affect either 
glycerol or FFA concentrations, consistent with 
previous reports in the FVB mouse background (48, 49). Moreover, 
hepatic phosphoenolpyruvate carboxykinase (PEPCK) expression 
was induced to the same extent in fasted Myh6/Ghrl and WT lit-
termates (Supplemental Figure 2I). Together, these data suggest 
that muscle wasting–resistant properties of Myh6/Ghrl mice do not 
depend on effects of UnAG on energy balance.
Furthermore, Myh6/Ghrl mice were protected from denervation-
induced muscle atrophy, an experimental procedure that does not 
affect animal daily food intake (Table 1). At 7 and 14 days after 
denervation, gastrocnemii weight of WT animals was reduced by 
21% and 27%, respectively, while the loss of muscle weight in Myh6/
Ghrl animals was significantly lower (Figure 4A). Consistently, gas-
trocnemii mean fiber CSA of WT animals was remarkably reduced 
at both 7 and 14 days after denervation, whereas CSA in Myh6/Ghrl 
animals was reduced to a lesser extent (Figure 4B). At 7 days after 
denervation, Myh6/Ghrl mice featured a mild shift of gastrocnemii 
CSA distribution that became impressive after 14 days (Figure 4, C 
and D). A strong inhibition of atrophy at 7 days after denervation 
was also evident in EDL (Figure 4, E and F) and tibialis anterior 
(TA) muscles (Figure 4, G and H).
Moreover, in gastrocnemii of Myh6/Ghrl mice, the induction of 
Atrogin-1 was reduced by 40% (Figure 4I). Conversely, MuRF1 was 
only slightly, not significantly, reduced (Figure 4J), consistent with 
the fasting-induced atrophy data. Together, these observations 
indicated that constitutive high levels of UnAG impair experimen-
tally induced atrophy in vivo, likely through a mechanism inde-
pendent of GHSR-1a and activation of the GH/IGF-1 axis.
UnAG pharmacological treatment induces antiatrophic signaling in 
muscle and inhibits fasting- and denervation-induced atrophy. Acute 
Table 1
Phenotypical characterization of Myh6/Ghrl mice
 WT Myh6/Ghrl
UnAG (pg/ml) 445.4 ± 155 25,000.5 ± 360A
AG, fed (pg/ml) 41.7 ± 1.6 39.3 ± 1.5
AG, fasted (pg/ml) 75.7 ± 8.8 68.2 ± 9.5
IGF-1, fed (ng/ml) 748.5 ± 56 765.5 ± 120
IGF-1, fasted (ng/ml) 398 ± 93 328 ± 37
Insulin (pg/ml) 571 ± 58 631 ± 129
Tibial length (mm) 19.65 ± 0.11 19.62 ± 0.22
Nasoanal length (mm) 91.59 ± 0.51 90.61 ± 0.95
BMI, fed (g/cm2) 3.32 ± 0.12 3.33 ± 0.08
BMI, fasted (g/cm2) 2.93 ± 0.06 2.92 ± 0.09
Gastrocnemius weight, fed (mg) 134.86 ± 4.6 137.2 ± 5.62
Gastrocnemius weight, fasted (mg) 118 ± 4 124 ± 3.1
Gastrocnemius weight/tibial length, fed (mg/mm) 6.86 ± 0.22 6.99 ± 0.25
Gastrocnemius weight/tibial length, fasted (mg/mm) 5.89 ± 0.14 6.36 ± 0.15B
Heart weight, fed (mg) 117.5 ± 11.8 122 ± 6.8
Heart weight, fasted (mg) 103.0 ± 7.1 105 ± 3.3
Heart weight/nasoanal length, fed (mg/mm) 1.22 ± 0.12 1.28 ± 0.08
Heart weight/nasoanal length, fasted (mg/mm) 1.16 ± 0.07 1.16 ± 0.03
Daily food intake (g) 4.66 ± 0.17 4.73 ± 0.07
Daily food intake, denervated (g) 4.60 ± 0.17 4.60 ± 0.18
Measurements were performed as described in Methods. Muscle mass and tibial length 
were calculated as the mean of right and left hindlimbs. n = 7 per group (fed); 4 per group 
(fasted 48 hours); 5 per group (denervated). Data are mean ± SEM. AP < 0.01 vs. WT.  
BP < 0.05 vs. WT.
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administration of exogenous UnAG at 100 μg/kg, a dose previ-
ously used for in vivo studies (6), induced phosphorylation of 
AktS473, FoxO3aT32, and p38T180/Y182 in WT gastrocnemii (Figure 5, 
A–C), which indicates that, in vivo, UnAG activates the same antia-
trophic signaling pathway as it does in C2C12 myotubes.
Repeated administration (every 12 hours) of UnAG protected 
mice from skeletal muscle atrophy induced by either fasting or 
denervation (Figure 5, D–I). UnAG treatment preserved gastroc-
nemii from weight and mean fiber CSA loss (Figure 5, D and E). 
Accordingly, frequency distribution of gastrocnemii CSA of fasted 
mice injected with UnAG showed a dramatic shift toward bigger 
fiber areas compared with saline-injected mice (Figure 5F).
Similarly, UnAG treatment of denervated mice resulted in a 25% 
protection from gastrocnemius weight loss and a significantly 
lower decrease of mean fiber CSA, although the CSA distribution 
of UnAG-injected mice showed only a very mild shift compared 
with saline-injected animals (Figure 5, G–I). Although the plasma 
concentration of UnAG after injection dropped to basal levels 
in about 2–4 hours (Supplemental Figure 3A), these data indi-
cate that repeated acute stimulation is sufficient to protect from 
experimentally induced skeletal muscle atrophy without affecting 
muscular IGF-1 expression (Supplemental Figure 3B).
AG and UnAG induce antiatrophic 
signaling and impair muscle atro-
phy in Ghsr–/– mice. The findings 
reported above, along with pre-
vious data on common binding 
sites for AG/UnAG in C2C12 
lacking Ghsr (16), strongly sug-
gest that AG and UnAG stimulate 
antiatrophic signaling in skeletal 
muscle through activation of a 
receptor distinct from GHSR-
1a. To verify this hypothesis, we 
assayed AG/UnAG antiatrophic 
signaling and activity in Ghsr–/– 
mice, in which AG fails to activate 
the GH/IGF-1a axis or stimulate 
appetite (50). Injection of either 
AG or UnAG induced AktS473 
phosphorylation in gastrocnemii 
of Ghsr–/– mice (Figure 6A). Con-
sistently, treatment of Ghsr–/– 
mice with 100 μg/kg AG or UnAG 
twice daily reduced gastrocnemii 
weight loss induced by 48-hour 
fasting by 30% compared with 
saline-treated animals (Figure 
6B). Moreover, the mean CSA loss 
of AG- and UnAG-injected mice 
strongly decreased compared with 
saline-injected animals, and CSA 
distribution shifted toward bigger 
areas (Figure 6, C and D).
In summary, these findings 
demonstrated that both AG and 
UnAG activate a direct antia-
trophic signaling pathway in 
skeletal muscle and protect from 
experimentally induced muscle 
atrophy, independently of the AG receptor GHSR-1a.
Discussion
Several studies have shown that AG protects from cachexia and 
prevents muscle proteolysis in vivo, supposedly through stim-
ulation of appetite and activation of the GH/IGF-1 axis medi-
ated by AG binding to GHSR-1a (6, 7, 18–21). However, here we 
provided in vitro and in vivo evidence that AG and UnAG exert 
antiatrophic activity by acting directly on the skeletal muscle, 
even in Ghsr–/– mice.
Upregulation of circulating UnAG, which does not bind GHSR-
1a and does not activate the GH/IGF-1 axis, counteracted muscle 
atrophy induced by either fasting or denervation. Consistently, 
UnAG has been reported to reduce burn-induced skeletal muscle 
proteolysis and local TNF-α upregulation (51).
We achieved upregulation of circulating UnAG either by myocar-
dial Ghrl overexpression in Myh6/Ghrl mice or by repeated admin-
istration. The antiatrophic activity of UnAG cannot be mediated 
by its conversion to AG in the plasma, since acylation occurs only 
intracellularly on the ghrelin precursor by the ghrelin-specific acyl-
transferase GOAT (11, 12). The negligible myocardial expression 
of GOAT might explain the increase of only the unacylated form 
Figure 3
Myh6/Ghrl mice are protected from skeletal muscle atrophy induced by 48 hours of fasting. (A–C) 
Effect of fasting on gastrocnemii. Mean percentage of gastrocnemius weight loss (A) and CSA reduc-
tion (B) of fasted Myh6/Ghrl (Tg) mice and WT littermates compared with fed animals. (C) Frequency 
distribution of gastrocnemii CSA of fasted Myh6/Ghrl and WT mice. (D–F) Effect of fasting on EDL 
muscles. Mean percentage of EDL muscle weight loss (D), CSA reduction (E), and CSA frequency 
distribution (F) of fasted Myh6/Ghrl and WT littermates. (G and H) Atrogin-1 and MuRF1 expression 
in gastrocnemii of fed and fasted Myh6/Ghrl mice and their WT littermates, determined by real-time 
RT-PCR. *P < 0.01 vs. WT. n = 7 (fed WT and Myh6/Ghrl); 5 (fasted WT); 6 (fasted Myh6/Ghrl); 3 (CSA 
loss and distribution, WT and Myh6/Ghrl).
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of circulating ghrelin in Myh6/Ghrl mice. This is in agreement with 
other tissue-specific Ghrl Tg mice featuring high UnAG circulating 
levels in the absence of significant changes of AG (43–45).
The observations that Myh6/Ghrl mice did not feature any 
change in circulating and muscular IGF-1 or in tibial or whole 
body length, along with the lack of skeletal muscle hypertrophy, 
further indicate that the GH/IGF-1 axis is not activated in these 
mice. Finally, the finding that both AG and UnAG impaired skele-
tal muscle atrophy in Ghsr–/– mice indicated that their antiatrophic 
activity is mediated by a receptor distinct from GHSR-1a. In these 
mice, AG exerted antiatrophic activity in the skeletal muscle inde-
pendent of its role in modulating GH release and energy balance. 
Nevertheless, these data do not exclude the possibility that in WT 
animals, GHSR-1a may contribute to the antiatrophic activity of 
AG by also regulating the GH/IGF-1 axis and positive energy bal-
ance. For instance, AG has been suggested to prevent downregu-
lation of muscular IGF-1 expression in an experimental model 
of cachexia through an indirect mechanism involving GHSR-1a 
activity on positive energy balance (20).
The hypothesis that AG/UnAG impairs muscle atrophy in vivo 
by acting directly on the skeletal muscle is further supported by 
our finding that UnAG administration rapidly stimulated anti-
atrophic signaling in the gastrocnemius. Moreover, AG/UnAG 
activated antiatrophic signaling in cultures of C2C12 myotubes, 
which do not express GHSR-1a, protecting them from dexameth-
asone-induced atrophy and atrogene upregulation. Although AG 
has previously been reported to fail in reducing dexamethasone-
induced Atrogin-1 expression in C2C12 myotubes (20), the 10-fold 
lower dexamethasone concentration used in that study and the 
considerably weaker Atrogin-1 induction may explain the differ-
ent results. Conversely, Sheriff et al. showed that UnAG reduces 
TNF-α/IFN-γ–induced cachexia in C2C12 myotubes in a PI3K/
mTOR-dependent manner (51). The results of our present study 
not only confirmed the involvement of PI3K/mTOR pathways in 
AG/UnAG activity on skeletal muscle, but also showed the spe-
cific contribution of the mTORC2- over the mTORC1-mediated 
signaling pathway, which may explain, at least in part, the ability 
of AG/UnAG to protect from skeletal muscle atrophy without a 
concomitant induction of hypertrophy.
Indeed, the molecular mechanisms underlying AG/UnAG antia-
trophic activity in the skeletal muscle involved the activation of 
mTORC2-mediated signaling pathways, leading to phosphoryla-
tion of AktS473 and of its substrate FoxO3aT32, which eventually 
impaired Atrogin-1 expression and muscle protein degradation. At 
Figure 4
Myh6/Ghrl mice are protected from denervation-induced skeletal muscle atrophy induced by sciatic nerve resection. (A and B) Mean percent-
age of weight loss (A) and CSA reduction (B) of denervated gastrocnemius at 7 and 14 days after denervation, compared with the unperturbed 
side. (C and D) Frequency distribution of gastrocnemii CSA at 7 and 14 days after denervation in Myh6/Ghrl and WT mice. (E–H) CSA reduction 
and fiber area distribution of (E and F) EDL and (G and H) TA muscles at 7 days after denervation. (I and J) Atrogin-1 and MuRF1 expression, 
determined by real-time RT-PCR, in denervated gastrocnemii at 7 days after denervation, compared with the unperturbed side. **P < 0.01, 
*P < 0.05 vs. WT. n = 6 (WT); 5 (Myh6/Ghrl); 3 (CSA loss and distribution, WT and Myh6/Ghrl).
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the same time, in C2C12 myotubes, AG/UnAG failed to stimulate 
mTORC1-mediated phosphorylation of S6KT389 and S6S235/236, pro-
tein synthesis, and hypertrophy. Consistently, chronic upregulation 
of circulating UnAG in Myh6/Ghrl mice did not induce muscle 
hypertrophy. This finding highlights a remarkable difference 
between the antiatrophic activities of AG/UnAG and IGF-1 in 
the skeletal muscle, as IGF-1 stimulates both mTORC2-mediat-
ed impairment of protein degradation and mTORC1-dependent 
stimulation of protein synthesis and hypertrophy (23–26). Consis-
tently, in TNF-α/IFN-γ–treated C2C12 myotubes, UnAG inhibited 
protein catabolism and impaired the induction of Atrogin-1 and 
MuRF1. Moreover, UnAG restored the basal phosphorylation state 
of proteins of mTORC1 and mTORC2 pathways, although the lack 
of UnAG-induced increase in AktS473 phosphorylation observed 
herein may depend on receptor desensitization, given the higher 
concentration of UnAG used and the protracted treatment (51).
The finding that downregulation of the mTORC1-specific 
component raptor did not affect the antiatrophic activity of AG/
UnAG, while impairing IGF-1 antiatrophic activity, further sup-
ports the conclusion that AG/UnAG antiatrophic activity does not 
involve mTORC1-mediated stimulation of protein synthesis. On 
the other hand, the finding that AG/UnAG antiatrophic activity 
was sensitive to downregulation of rictor, the specific component 
of mTORC2, demonstrated the key role of mTORC2 in mediating 
AG/UnAG antiatrophic activity. The finding that ghrelin-induced 
phosphorylation of AktS473 was uncoupled from the activation of 
mTORC1-mediated pathways and hypertrophy may appear con-
troversial, as IGF-1–induced phosphorylation of AktS473 is associ-
ated with the activity of both mTOR complexes (29), and overex-
pression of constitutive active Akt in the skeletal muscle prevents 
denervation-induced atrophy and induces hypertrophy (22, 52). 
The lack of muscle hypertrophy observed in Myh6/Ghrl mice may 
depend on weaker stimulation of the PI3K/Akt pathway by UnAG. 
Indeed, although tissue-specific expression of constitutive active 
Akt in Tg mice induces strong phosphorylation of Akt and of 
its substrates (53), phosphorylation of Akt was not detectable in 
Figure 5
UnAG pharmacological treatment protects skeletal muscle from fasting- and denervation-induced atrophy in WT mice. (A–C) Phosphorylation of 
AktS473, FoxO3aT32, and p38T180/Y182 in gastrocnemii of WT mice treated with 100 μg/kg UnAG or saline. At the indicated time points, gastrocnemii 
were removed and processed for Western blot analysis. Shown are representative blots and densitometric analysis of 3 independent experi-
ments, normalized to untreated animals (not shown). (D–F) Mean percent weight loss (D), CSA reduction (E), and CSA frequency distribution 
(F) of gastrocnemii from fed or 48-hour fasted mice treated twice daily with 100 μg/kg UnAG or saline (n = 5 per group). Frequency distribution 
was measured in 3 mice per group. In D and E, percent reduction shown is between fasted and fed mice. (G–I) Mean percent weight loss (G), 
CSA reduction (H), and CSA frequency distribution (I) of gastrocnemii from mice treated with 100 μg/kg UnAG or saline twice daily for 7 days 
after sciatic nerve resection (n = 5 per group). Frequency distribution was measured in 3 mice per group. In G and H, percent reduction shown is 
between denervated gastrocnemii and gastrocnemii from the unperturbed side. *P < 0.05, **P < 0.01 vs. saline treatment.
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muscles of Myh6/Ghrl mice (data not shown). Indeed, we found 
that 2 distinct PI3K isoforms, namely PI3Kβ and PI3Kα, mediated 
the antiatrophic activity of AG/UnAG and IGF-1, respectively. This 
observation, along with the ability of a Gαs-uncoupling drug to 
abolish the antiatrophic activity of AG/UnAG, but not IGF-1, is 
consistent with the hypothesis that the unknown receptor mediat-
ing the common activities of AG/UnAG is a GPCR (9). Moreover, 
these data further serve to rule out the hypothesis that AG/UnAG 
acts on myotubes by stimulating the autocrine release of IGF-1.
The inability of AG and UnAG to stimulate protein synthesis and 
hypertrophy in the skeletal muscle is consistent with their key role 
in the adaptive response to fasting and negative energy balance 
(13). The molecular mechanisms underlying the uncoupling of 
mTORC2 from mTORC1 remain to be investigated. AG and UnAG, 
which are released during fasting, might shift muscle metabolism 
toward amino acid oxidation, thereby decreasing the intracellular 
pool of free amino acids essential for mTORC1 activity (29). Alter-
natively, activation of PI3Kβ, whose enzymatic activity is lower than 
that of PI3Kα (54), may result in weaker activation of Akt. Finally, 
AMPK, which negatively regulates mTORC1 in skeletal muscle 
(55), may contribute to mTORC1 uncoupling, although AG was 
reported to be unable to stimulate AMPK in rat gastrocnemius (56).
The finding that p38 was required for AG/UnAG antiatrophic 
activity is consistent with previous findings that p38 cooperates 
with PI3K/Akt pathways to induce C2C12 differentiation (16, 57). 
However, the role of p38 in regulating muscle atrophy is complex, as 
its activation mediates muscle atrophy induced by oxidative stress 
and inflammatory cytokines (34, 36, 58). The role of p38 in signal-
ing is determined by its association in distinct signaling complexes 
with different regulators and substrates and by its localization 
(35). Our findings are consistent with evidence indicating that, in 
myotubes, decreased p38 phosphorylation is associated with dexa-
methasone-induced atrophy, and that p38 mediates β-hydroxyl- 
β-methylbutyrate protection from dexamethasone-induced protein 
degradation (59, 60). Moreover, p38 activity can regulate cytoplas-
mic localization of FoxO3a independently of Akt, thereby impairing 
its transcriptional activity and Atrogin-1 induction (33, 61). Fur-
thermore, activation of p38 stabilizes and activates the transcrip-
tional coactivator PGC1α, which represses FoxO3a activity (62, 
63). Although IGF-1 activated p38, this was dispensable for IGF-1 
antiatrophic activity. In addition, IGF-1 and AG/UnAG antiatrophic 
activities differed in the inability of AG/UnAG to downregulate 
myostatin, a TGF-β–like inhibitor of muscle growth, which further 
supports the hypothesis that AG/UnAG and IGF-1 counteract mus-
cle atrophy through distinct molecular mechanisms.
The data presented herein unveiled a novel component of the 
complex role of AG/UnAG, i.e., the direct activation of antia-
trophic pathways in the skeletal muscle, eventually leading to 
reduced muscle wasting. This effect adds to the well-known capa-
bilities of AG to stimulate appetite, regulate lipid metabolism, and 
release GH. Although the identity of the novel AG/UnAG receptor 
is yet unknown, these findings may have important biological and 
therapeutic implications, since they provide proof that UnAG has 
a strong and specific potential for the prevention or treatment of 
muscle atrophy, avoiding the diabetogenic side effects of AG (47) 
and the cancer risk associated with IGF-1 treatment (64).
Methods
Reagents. AG1–28 and UnAG1–28 were purchased from PolyPeptide Laborato-
ries. The PI3K p110α inhibitor PIK-75 hydrochloride was purchased from 
Axon Medchem, and the PI3K p110β inhibitor TGX-221 was a gift from 
U. Galli (Synthetic Medicinal Chemistry group, Università del Piemonte 
Orientale, Novara, Italy). Water-soluble dexamethasone and all other 
reagents, unless otherwise stated, were from Sigma-Aldrich. Anti–phos-
pho-AktS473, anti-Akt, anti–phospho-FoxO3aT32, anti-FoxO3a, anti–phos-
pho-S6KT389, anti-S6K, anti–phospho-S6S235/236, anti-S6, anti-p38T180/Y182, 
anti-p38, anti-raptor, and anti-rictor antibodies were from Cell Signaling 
Technology; anti-actin antibody was from Santa Cruz Biotechnology.
Cell cultures and myotube analysis. C2C12 myoblasts were differentiated in 
myotubes as previously described (16). For measurement of myotube diam-
Figure 6
AG and UnAG pharmacological treatment of 
Ghsr–/– mice induces antiatrophic signaling and 
protects from fasting-induced skeletal muscle 
atrophy. (A) Phosphorylation of AktS473 in gas-
trocnemii of Ghsr–/– mice injected with 100 μg/
kg AG or UnAG or with saline. 60 minutes after 
treatment, gastrocnemii were removed and pro-
cessed for Western blot analysis. Shown are 
representative blots and densitometric analysis 
of 3 independent experiments. (B–D) Mean per-
centage weight loss (B), CSA reduction (C), and 
CSA frequency distribution (D) of gastrocnemii 
from fed or 48-hour fasted Ghsr–/– mice injected 
s.c. twice daily with 100 μg/kg AG or UnAG or 
with saline (n = 5 per group). Frequency distribu-
tion was measured in 3 mice per group. In B and 
C, percent reduction is between fasted and fed 
mice. *P < 0.05, **P < 0.01 vs. saline treatment.
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blood glucose meter (Roche Diagnostics). For insulin sensitivity determina-
tion, Humulin R (0.75 U/kg body weight; Lilly) was administered i.p., and 
blood samples for glucose concentrations were collected as described above.
RNA extraction and analysis. Total RNA from cultured myotubes and from 
muscles was extracted by TRIreagent (Invitrogen). The RNA was retro-tran-
scribed with High-Capacity cDNA Reverse Transcription Kit (Invitrogen), 
and real-time PCR was performed with the ABI7200 Sequence Detection 
System (Invitrogen) using the following assays: Mm00499518_m1 (Fbxo32, 
Atrogin-1), Mm01185221_m1 (Trim63, MuRF1), Mm00439560_m1 (Igf1), 
Mm00445450_m1 (Ghrl), Mm01254559_m1 (Mstn), Mm01247058_m1 
(Pck1), Mm00446953_m1 (Gusb), and Mm00506384_m1 (Ppif).
Muscle sampling and staining for fiber size assessment. Muscles were embed-
ded in Killik compound (Bio-optica) and frozen in liquid nitrogen–cooled 
isopentane. Serial transverse cryosections (7 μm thick) of the midbelly 
region of muscles were cut at –20°C and mounted on glass slides. The 
sections were air-dried, fixed for 10 minutes in 4% paraformaldehyde, and 
stained with H&E. The number of myofibers in TA, gastrocnemii, and EDL 
was measured from the histological preparations. Muscle fiber CSA was 
assessed as previously described (67). Data are expressed as fiber size dis-
tribution and as percent CSA reduction relative to controls.
Grip strength test. Skeletal muscle force was assessed using the BS-GRIP 
Grip Meter (2Biological Instruments) as previously described (68). Each 
animal was tested 3 times, and the average value of the maximum weight 
that the animal managed to hold was recorded and normalized to the 
mouse’s weight.
Statistics. Data are presented as mean ± SEM. Variation among groups 
was evaluated using nonparametric Wilcoxon and Mann-Whitney U tests. 
Statistical significance was assumed for P values less than 0.05. All statisti-
cal analyses were performed with SPSS for Windows version 17.0.
Study approval. All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee at Università del Piemonte 
Orientale “Amedeo Avogadro.”
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eters, myotubes were fixed, and diameters were quantified by measuring a 
total of >100 myotube diameters from 5 random fields in 3 replicates at 
×40 magnification using Image-Pro Plus software (MediaCybernetics) as 
described previously (24).
Raptor and rictor silencing. Raptor siRNA (MISSION pre-designed siRNA SASI_
Mm01_00055293; Sigma-Aldrich), rictor siRNA (SASI_Mm01_00137731; 
Sigma-Aldrich), Block-iT, or siRNA negative control sequence (Invitrogen) 
were transfected with Lipofectamine2000 (Invitrogen) in C2C12 myotubes. 
Transfection efficiency was evaluated by the fluorescent siRNA negative 
control Block-iT, and silencing was verified by Western blot.
[3H]-leucine incorporation assay. C2C12 myotubes were maintained for 
24 hours with or without 10 nM AG or UnAG in differentiation medium 
supplemented with 2 μCi/ml [3H]-leucine (Perkin Elmer) to evaluate the 
induction of protein synthesis. At the end of treatments, cells were washed 
with PBS, treated with 5% trichloroacetic acid, and lysed with 0.5 M 
NaOH and 0.5% SDS. The amount of incorporated [3H]-leucine was evalu-
ated by β counter (Tri-Carb 2800TR; Perkin Elmer) analysis. Data are the 
average of 4 replicates.
Western blot. C2C12 myotubes were serum starved overnight and then 
treated as indicated in the figure legends. Western blot was performed as pre-
viously described (16). Unless otherwise specified, after use of anti–phospho-
specific antibodies, membranes were stripped with Re-Blot Plus (Chemicon, 
Millipore) and reblotted with the corresponding total protein antibodies.
Muscles of mice fasted for 6 hours were s.c. injected with 100 μg/kg 
UnAG or AG or with saline solution. At the indicated time points, gas-
trocnemii were removed, homogenized at 4°C in RIPA buffer (1% Triton 
X-100; 1% sodium deoxycholate; 0.1% SDS; 1 mM EDTA; 1 mM EGTA; 
50 mM NaF; 160 mM NaCl; and 20 mM Tris-HCl, pH 7.4) containing 
1 mM DTT, protease inhibitor cocktail, and 1 mM Na3VO4. Homogenates 
were then processed as above.
Tg animal generation and treatment. All experiments were conducted on 
young adult male FVB1 WT, FVB1 Myh6/Ghrl, and C57BL/6J Ghsr–/– mice 
(50), matched for age and weight.
Tg animals were obtained by cloning the murine ghrelin gene (Ghrl) 
under control of the cardiac promoter sequences of the β myosin heavy 
chain 3′ UTR and the first 3 exons of the α isoform Myh6 (65). Transgene 
integration and expression were confirmed by PCR and real-time RT-PCR, 
respectively. Phenotypical characterization and experiments were carried 
out on hemizygote animals and littermate controls.
AG, UnAG, and IGF-1 plasmatic levels were measured by EIA kits (SPIbio 
Bertin Pharma for AG and UnAG; R&D Systems for IGF-1); insulin plas-
matic levels were quantified with the Insulin (mouse) ELISA kit (ALPCO 
Diagnostics); and glycerol and free fatty acid plasmatic levels were evalu-
ated by enzymatic assay kits (Cayman).
BMI was calculated as animal weight divided by the square of the 
nasoanal length.
Fasting-induced atrophy was achieved by 48 hours of food removal (63), 
while denervation-induced muscle atrophy was obtained by resection of 
the sciatic nerve under anesthesia with sevoflurane (Baxter) and evaluated 
7 and 14 days later (66). Muscles were collected, weighed, and normalized 
for tibial length and processed either for RNA extraction or for histology.
Daily food intake was measured over a 12-day period, quantifying the 
food consumption of each mouse every day.
In all experiments with s.c. injection of AG and/or UnAG, controls were 
saline-injected animals.
Glucose and insulin tolerance tests. Glucose tolerance and insulin sensitivity 
tests were performed as previously described (43). For glucose tolerance 
evaluation, mice were injected i.p. with glucose at 1.5 mg/g body weight 
at 9:00 am, after 16 hours of fasting. Blood glucose was determined at the 
indicated time points on tail blood samples using the Accu-Chek Mobile 
research article
 The Journal of Clinical Investigation   http://www.jci.org 11
 1. Dodson S, et al. Muscle wasting in cancer cachexia: 
clinical implications, diagnosis, and emerging treat-
ment strategies. Annu Rev Med. 2011;62:265–279.
 2. Kojima M, Hosoda H, Date Y, Nakazato M. Ghre-
lin is a growth-hormone-releasing acylated peptide 
from stomach. Nature. 1999;402(6762):656–660.
 3. Tschöp M, Smiley DL, Heiman ML. Ghre-
lin induces adiposity in rodents. Nature. 2000; 
407(6806):908–913.
 4. Nakazato M, Murakami N, Date Y, Kojima M. A 
role for ghrelin in the central regulation of feeding. 
Nature. 2001;409(6817):194–198.
 5. Howard AD, Feighner SD, Cully DF, Arena JP. A 
receptor in pituitary and hypothalamus that func-
tions in growth hormone release. Science. 1996; 
273(5277):974–977.
 6. Nagaya N, et al. Chronic administration of ghrelin 
improves left ventricular dysfunction and attenu-
ates development of cardiac cachexia in rats with 
heart failure. Circulation. 2001;104(12):1430–1435.
 7. Nagaya N, et al. Effects of ghrelin administration 
on left ventricular function, exercise capacity, and 
muscle wasting in patients with chronic heart fail-
ure. Circulation. 2004;110(24):3674–3679.
 8. Baldanzi G, et al. Ghrelin and des-acyl ghrelin 
inhibit cell death in cardiomyocytes and endothelial 
cells through ERK1/2 and PI 3-kinase/AKT. J Cell 
Biol. 2002;159(6):1029–1037.
 9. Granata R, et al. Acylated and unacylated ghrelin 
promote proliferation and inhibit apoptosis of pan-
creatic beta-cells and human islets: involvement of 
3′,5′-cyclic adenosine monophosphate/protein 
kinase A, extracellular signal-regulated kinase 1/2, 
and phosphatidyl inositol 3-Kinase/Akt signaling. 
Endocrinology. 2007;148(2):512–529.
 10. Chung H, Seo S, Moon M, Park S. Phosphatidylino-
sitol-3-kinase/Akt/glycogen synthase kinase-3 
beta and ERK1/2 pathways mediate protective 
effects of acylated and unacylated ghrelin against 
oxygen-glucose deprivation-induced apoptosis in 
primary rat cortical neuronal cells. J Endocrinol. 
2008;198(3):511–521.
 11. Yang J, Brown MS, Liang G, Grishin NV, Gold-
stein JL. Identification of the acyltransferase that 
octanoylates ghrelin, an appetite-stimulating 
peptide hormone. Cell. 2008;132(3):387–396.
 12. Gutierrez JA, et al. Ghrelin octanoylation mediated 
by an orphan lipid transferase. Proc Natl Acad Sci U S A. 
2008;105(17):6320–6325.
 13. Chen C-Y, Asakawa A, Fujimiya M, Lee S-D, Inui 
A. Ghrelin gene products and the regulation of 
food intake and gut motility. Pharmacol Rev. 2009; 
61(4):430–481.
 14. Delhanty PJD, et al. Ghrelin and unacylated ghrelin 
stimulate human osteoblast growth via mitogen-
activated protein kinase (MAPK)/phosphoinosit-
ide 3-kinase (PI3K) pathways in the absence of 
GHS-R1a. J Endocrinol. 2006;188(1):37–47.
 15. Sato M, et al. Effects of ghrelin and des-acyl ghrelin 
on neurogenesis of the rat fetal spinal cord. Biochem 
Biophys Res Commun. 2006;350(3):598–603.
 16. Filigheddu N, et al. Ghrelin and des-acyl ghrelin 
promote differentiation and fusion of C2C12 skel-
etal muscle cells. Mol Biol Cell. 2007;18(3):986–994.
 17. Delhanty PJD, et al. Unacylated ghrelin rapidly 
modulates lipogenic and insulin signaling path-
way gene expression in metabolically active tissues 
of GHSR deleted mice. PLoS One. 2010;5(7):e11749.
 18. Nagaya N, et al. Treatment of cachexia with ghrelin in 
patients with COPD. Chest. 2005;128(3):1187–1193.
 19. Balasubramaniam A, et al. Ghrelin inhibits skeletal 
muscle protein breakdown in rats with thermal 
injury through normalizing elevated expression of 
E3 ubiquitin ligases MuRF1 and MAFbx. Am J Physi-
ol Regul Integr Comp Physiol. 2009;296(4):R893–R901.
 20. Sugiyama M, et al. Ghrelin improves body weight 
loss and skeletal muscle catabolism associated with 
angiotensin II-induced cachexia in mice. Regul Pept. 
2012;178(1–3):21–28.
 21. DeBoer MD. Emergence of ghrelin as a treatment for 
cachexia syndromes. Nutrition. 2008;24(9):806–814.
 22. Bodine SC, et al. Akt/mTOR pathway is a crucial 
regulator of skeletal muscle hypertrophy and can 
prevent muscle atrophy in vivo. Nat Cell Biol. 2001; 
t3(11):1014–1019.
 23. Rommel C, et al. Mediation of IGF-1-induced skel-
etal myotube hypertrophy by PI(3)K/Akt/mTOR 
and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 
2001;3(11):1009–1013.
 24. Sandri M, et al. Foxo transcription factors induce the 
atrophy-related ubiquitin ligase atrogin-1 and cause 
skeletal muscle atrophy. Cell. 2004;117(3):399–412.
 25. Stitt TN, et al. The IGF-1/PI3K/Akt pathway pre-
vents expression of muscle atrophy-induced ubiq-
uitin ligases by inhibiting FOXO transcription fac-
tors. Mol Cell. 2004;14(3):395–403.
 26. Latres E, et al. Insulin-like growth factor-1 (IGF-1) 
inversely regulates atrophy-induced genes via the 
phosphatidylinositol 3-kinase/Akt/mammalian 
target of rapamycin (PI3K/Akt/mTOR) pathway. 
J Biol Chem. 2005;280(4):2737–2744.
 27. Bodine SC, et al. Identification of ubiquitin ligas-
es required for skeletal muscle atrophy. Science. 
2001;294(5547):1704–1708.
 28. Foster KG, Fingar DC. Mammalian target of rapamy-
cin (mTOR): conducting the cellular signaling sym-
phony. J Biol Chem. 2010;285(19):14071–14077.
 29. Laplante M, Sabatini DM. mTOR signaling in growth 
control and disease. Cell. 2012;149(2):274–293.
 30. Copp J, Manning G, Hunter T. TORC-specific 
phos phorylation of mammalian target of rapamy-
cin (mTOR): phospho-Ser2481 is a marker for 
intact mTOR signaling complex 2. Cancer Res. 2009; 
69(5):1821–1827.
 31. Sarbassov DD, et al. Prolonged rapamycin treat-
ment inhibits mTORC2 assembly and Akt/PKB. 
Mol Cell. 2006;22(2):159–168.
 32. Lamming DW, et al. Rapamycin-induced insulin resis-
tance is mediated by mTORC2 loss and uncoupled 
from longevity. Science. 2012;335(6076):1638–1643.
 33. Clavel S, Siffroi-Fernandez S, Coldefy AS, Bou-
lukos K, Pisani DF, Dérijard B. Regulation of the 
intracellular localization of Foxo3a by stress-acti-
vated protein kinase signaling pathways in skeletal 
muscle cells. Mol Cell Biol. 2010;30(2):470–480.
 34. Li YP, et al. TNF-alpha acts via p38 MAPK to 
stimulate expression of the ubiquitin ligase atro-
gin1/MAFbx in skeletal muscle. FASEB J. 2005; 
19(3):362–370.
 35. Cuadrado A, Nebreda AR. Mechanisms and func-
tions of p38 MAPK signalling. Biochem J. 2010; 
429(3):403–417.
 36. McClung JM, Judge AR, Powers SK, Yan Z. p38 
MAPK links oxidative stress to autophagy-related 
gene expression in cachectic muscle wasting. Am J 
Physiol Cell Physiol. 2010;298(3):C542–C549.
 37. Kim J, et al. p38 MAPK participates in muscle-
specific RING Finger 1-mediated atrophy in cast-
immobilized rat gastrocnemius muscle. Korean J 
Physiol Pharmacol. 2009;13(6):491–496.
 38. Hohenegger M, et al. 1998. Gsalpha-selective G 
protein antagonists. Proc Natl Acad Sci U S A. 1998; 
95(1):346–351.
 39. Jia S, et al. Essential roles of PI(3)K-p110beta in cell 
growth, metabolism and tumorigenesis. Nature. 
2008;454(7205):776–779.
 40. Ciraolo E, et al. Phosphoinositide 3-kinase p110be-
ta activity: key role in metabolism and mammary 
gland cancer but not development. Sci Signal. 
2008;1(36):ra3.
 41. Morissette MR, Cook SA, Buranasombati C, Rosen-
berg MA, Rosenzweig A. Myostatin inhibits IGF-I-
induced myotube hypertrophy through Akt. Am J 
Physiol Cell Physiol. 2009;297(5):1124–1132.
 42. Trendelenburg AU, Meyer A, Rohner D, Boyle J, 
Hatakeyama S, Glass DJ. Myostatin reduces Akt/
TORC1/p70S6K signaling, inhibiting myoblast 
differentiation and myotube size. Am J Physiol Cell 
Physiol. 2009;296(6):C1258–C1270.
 43. Zhang W, Chai B, Li J-Y, Wang H, Mulholland MW. 
Effect of des-acyl ghrelin on adiposity and glucose 
metabolism. Endocrinology. 2008;149(9):4710–4716.
 44. Iwakura H, et al. Analysis of rat insulin II promot-
er-ghrelin transgenic mice and rat glucagon pro-
moter-ghrelin transgenic mice. J Biol Chem. 2005; 
280(15):15247–15256.
 45. Ariyasu H, et al. Transgenic mice overexpressing 
des-acyl ghrelin show small phenotype. Endocrinol-
ogy. 2005;146(1):355–364.
 46. Musarò A, et al. Localized Igf-1 transgene expression 
sustains hypertrophy and regeneration in senescent 
skeletal muscle. Nat Genet. 2001;27(2):195–200.
 47. Delhanty PJ, van der Lely AJ. Ghrelin and glucose 
homeostasis. Peptides. 2011;32(11):2309–2318.
 48. Mandard S, et al. The fasting-induced adipose fac-
tor/angiopoietin-like protein 4 is physically associ-
ated with lipoproteins and governs plasma lipid lev-
els and adiposity. J Biol Chem. 2006;281(2):934–944.
 49. Sharara-Chami RI, Zhou Y, Ebert S, Pacak K, Ozcan 
U, Majzoub JA. Epinephrine deficiency results in 
intact glucose counter-regulation, severe hepatic 
steatosis and possible defective autophagy in fast-
ing mice. Int J Biochem Cell Biol. 2012;44(6):905–913.
 50. Sun Y, Wang P, Zheng H, Smith RG. Ghrelin stimu-
lation of growth hormone release and appetite is 
mediated through the growth hormone secre-
tagogue receptor. Proc Natl Acad Sci U S A. 2004; 
101(13):4679–4684.
 51. Sheriff S, Kadeer N, Joshi R, Friend LA, James JH, 
Balasubramaniam A. Des-acyl ghrelin exhibits 
pro-anabolic and anti-catabolic effects on C2C12 
myotubes exposed to cytokines and reduces burn-
induced muscle proteolysis in rats. Mol Cell Endocri-
nol. 2012;351(2):286–295.
 52. Pallafacchina G, Calabria E, Serrano AL, Kalhovde 
JM, Schiaffino S. A protein kinase B-dependent 
and rapamycin-sensitive pathway controls skeletal 
muscle growth but not fiber type specification. Proc 
Natl Acad Sci U S A. 2002;99(14):9213–9218.
 53. Skurk C, et al. The FOXO3a transcription factor 
regulates cardiac myocyte size downstream of AKT 
signaling. J Biol Chem. 2005;280(21):20814–20823.
 54. Zhao JJ, et al. The p110alpha isoform of PI3K is 
essential for proper growth factor signaling and 
oncogenic transformation. Proc Natl Acad Sci U S A. 
2006;103(44):16296–16300.
 55. Gwinn DM, et al. AMPK phosphorylation of raptor 
mediates a metabolic checkpoint. Mol Cell. 2008; 
30(2):214–226.
 56. Barazzoni R, et al. Ghrelin regulates mitochon-
drial-lipid metabolism gene expression and tissue 
fat distribution in liver and skeletal muscle. Am J 
Physiol Endocrinol Metab. 2005;288(1):E228–E235.
 57. Serra C, et al. Functional interdependence at the 
chromatin level between the MKK6/p38 and IGF1/
PI3K/AKT pathways during muscle differentia-
tion. Mol Cell. 2007;28(2):200–213.
 58. Puigserver P, et al. Cytokine stimulation of energy 
expenditure through p38 MAP kinase activa-
tion of PPARgamma coactivator-1. Mol Cell. 2001; 
8(5):971–982.
 59. Kewalramani G, et al. Acute dexamethasone-induced 
increase in cardiac lipoprotein lipase requires activa-
tion of both Akt and stress kinases. Am J Physiol Endo-
crinol Metab. 2008;295(1):E137–E147.
 60. Aversa Z, Alamdari N, Castillero E, Muscaritoli M, 
Rossi Fanelli F, Hasselgren PO. beta-Hydroxy-beta-
methylbutyrate (HMB) prevents dexamethasone-
induced myotube atrophy. Biochem Biophys Res 
Commun. 2012;423(4):739–743.
 61. Qin W, Pan J, Wu Y, Bauman WA, Cardozo C. Pro-
tection against dexamethasone-induced muscle 
atrophy is related to modulation by testosterone of 
FOXO1 and PGC-1α. Biochem Biophys Res Commun. 
research article
12 The Journal of Clinical Investigation   http://www.jci.org
2010;403(3–4):473–478.
 62. Hong T, et al. Fine-tuned regulation of the PGC-
1α gene transcription by different intracellular 
signaling pathways. Am J Physiol Endocrinol Metab. 
2011;300(3):E500–E507.
 63. Sandri M, et al. PGC-1alpha protects skeletal mus-
cle from atrophy by suppressing FoxO3 action and 
atrophy-specific gene transcription. Proc Natl Acad 
Sci U S A. 2006;103(44):16260–16265.
 64. Fürstenberger G, Senn HJ. Insulin-like growth fac-
tors and cancer. Lancet Oncol. 2002;3(5):298–302.
 65. De Acetis M, et al. Cardiac overexpression of 
melusin protects from dilated cardiomyopathy due 
to long-standing pressure overload. Circ Res. 2005; 
96(10):1087–1094.
 66. Hishiya A, Iemura S, Natsume T, Takayama S, 
Ikeda K, Watanabe K. A novel ubiquitin-binding 
protein ZNF216 functioning in muscle atrophy. 
EMBO J. 2006;25(3):554–564.
 67. Geuna S, Tos P, Guglielmone R, Battiston B, Giaco-
bini-Robecchi MG. Methodological issues in size 
estimation of myelinated nerve fibers in peripheral 
nerves. Anat Embryol (Berl). 2001;204(1):1–10.
 68. Tos P, et al. Employment of the mouse median 
nerve model for the experimental assessment of 
peripheral nerve regeneration. J Neurosci Methods. 
2008;169(1):119–127.
